A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The goal of this intervention study is to evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HXN5003 in Healthy Participants.The main parameters it aims to answer are: 1. Does a single dose of HXN5003 in healthy participants impact the safety, tolerability and pharmacokinetic profiles? 2. Will immunogenicity of HXN5003 in healthy participants be altered? This study will be compared against a Placebo which contains the same inactive ingredients as those of HXN5003, but without the active ingredient.
Epistemonikos ID: 43f94a49a7b31cc410a4178c6d0bb2da8d837ee7
First added on: Apr 25, 2026